[Resistance to antibiotics of Staphylococcus aureus responsible of osteoarticular infections].
Osteo-articular infections represent the majority of invasive Staphylococcus aureus infections in children. It is demonstrated that, independently of the resistance or susceptibility to methicillin, the production of Panton-Valentine leukocidin (PVL) by S. aureus enhanced the severity of the disease. However, an increase of the rate of community acquired methicillin-resistant S. aureus (CA-MRSA) has been reported in osteo-articular infections. These CA-MRSA are the most often susceptible to the other antibiotics. SCCmec elements of type IV or V associated with the PVL coding genes seem to be molecular markers of CA-MRSA. The risk factors of acquisition of these strains are the young age of children and the overcrowding. It is now established that CA-MRSA are pathogens present all over the world. It thus became necessary to look after the epidemiology of these virulent strains.
Raymond
J
J
Université Renée Descartes, Service de Bactériologie, Hôpital Cochin, 27 r Fbg St-Jacques 75014 Paris, France. j.raymond@svp.aphp.fr
Bergeret
M
M
D000328:Adult; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000096:biosynthesis / Q000235:genetics; D002648:Child; D002981:Clindamycin / Q000494:pharmacology; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D003603:Cytotoxins / Q000096:biosynthesis / Q000235:genetics; D005098:Exotoxins / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D007956:Leukocidins / Q000096:biosynthesis / Q000235:genetics; D008712:Methicillin / Q000494:pharmacology; D016106:Methicillin Resistance / Q000187:drug effects / Q000235:genetics; D008826:Microbial Sensitivity Tests; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D003603:Cytotoxins; D005098:Exotoxins; D007956:Leukocidins; C078284:Panton-Valentine leukocidin; D011500:Protein Synthesis Inhibitors; D002981:Clindamycin; D008712:Methicillin